A new Pfizer Animal Health was unveiled last week as Pfizer's acquisition of Wyeth, including its subsidiary Fort Dodge Animal Health, was completed. 

The acquisition of many of Fort Dodge’s U.S. products allows Pfizer Animal Health to greatly diversify its U.S. portfolio, as well as broaden its offering in all animal health segments. Pfizer Animal Health now offers an enhanced portfolio in beef, dairy, and companion animals, as well as a redefined product line for swine, equine and poultry.   

“We’re extremely proud to offer our customers even more best-in-class and innovative products,” said Clint Lewis, president of U.S Operations for Pfizer Animal Health. “The products, services and expertise we are gaining strengthen what is already a robust U.S. portfolio and will enhance our leading position in the animal-health marketplace.”

In the cattle market, Pfizer will further enhance its position with the addition of FACTREL (gonadorelin hydrochloride) and the proven and well-recognized pioneer line of SYNOVEX implants. These products complement the current U.S. cattle portfolio that includes DRAXXIN (tulathromycin), DECTOMAX, EXCEDE (ceftiofur crystalline free acid), EXCENEL (ceftiofur hydrochloride), BOVI-SHIELD GOLD, LUTALYSE (dinoprost tromethamine), ORBESEAL  and SPECTRAMAST (ceftiofur hydrochloride).  Pfizer Animal Genetics also continues to explore opportunities to apply genomics technology to livestock health and management solutions.

Pfizer Animal Health also announced today that all current U.S. pricing, product-distribution, programs and policies for Pfizer Animal Health products, including the acquired Fort Dodge products, will remain in place through 2009.

“Pfizer Animal Health is passionate about working hand-in-hand with our customers and partners to transform the care, health and well-being of animals,” Lewis said. “We continue to envision a future where animal health care providers, veterinarians and livestock producers look to Pfizer first to help them to run their practice or operation productively and profitably. With our newly expanded portfolio, value-added services and high-caliber talent, Pfizer is more focused than ever on providing relevant solutions to their animal care needs,” Lewis said.

Source: Pfizer Animal Health